海外のユーイング肉腫治療のベスト医師 — ページ2

マフムード・M・エル・ゼンベリ医師は、シェファ・アル・オルマンがんセンターの小児腫瘍科部長を務めています。小児腫瘍学および悪性血液学の専門医です。エル・ゼンベリ医師は、シアトルがんケア・アライアンスにて小児骨髄移植の臨床フェローシップを修了しました。白血病、リンパ腫、神経芽腫など、さまざまな小児がんの治療を行っています。

• あらゆる種類の小児白血病、ホジキンリンパ腫、非ホジキンリンパ腫を管理します。
• 腎芽腫、横紋筋肉腫、希少な小児がんなどの固形腫瘍を治療します。
• 小児患者に対する同種および自家骨髄移植を実施します。
• 年間6,000人の患者を治療するESMO認定センターで勤務しています。

ラーナン・バーガー博士は、シェバ医療センターがんセンターのセンター長です。2025年にはForbesイスラエルの「ベストドクター」リストに選出されました。バーガー博士は泌尿器腫瘍学を専門とし、複雑な前立腺腫瘍への放射線治療を行っています。ダナ・ファーバー/ハーバードがん研究所で博士研究員としてのフェローシップを修了しました。

• 分子腫瘍学に焦点を当てた臨床研究ユニットを統括。
• 前立腺がんとBRCA変異に関する20本以上の査読付き論文の共著者。
• 米国臨床腫瘍学会（ASCO）会員。
• 世界トップ10にランクされる病院で全身療法および放射線療法を実施。

アイリス・クヴェンツェル博士は、シェバ医療センターの小児血液腫瘍科医であり、骨髄移植の専門家です。エドモンド＆リリー・サフラ小児病院にて、ユーイング肉腫や骨肉腫などの小児肉腫を治療しています。クヴェンツェル博士は、複雑な小児がんに対して標的療法と細胞治療を統合した治療を行っています。また、テルアビブ大学医学部の教員も務めています。

• 小児患者に対する骨髄移植およびCAR-T細胞療法の専門家。
• Li-Fraumeni症候群や感受性遺伝子を含む、がんの遺伝的素因を研究。
• 幹細胞生物学および外科腫瘍学（HIPEC）に関する主要ジャーナルで論文を発表。
• 世界トップ10病院にランクされるシェバ医療センターに勤務。

ネタネル・メウシャール医師は、ランバム医療センターの骨腫瘍科を統括しています。

• 骨がん治療を専門とする
• 複雑な肉腫症例の管理において経験豊富
• イスラエルの主要な医療センターに勤務

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

ミリアム・ベン・アルシュ教授は、小児腫瘍学および骨髄移植の分野で国際的に認められた専門家であり、ルース・ラパポート小児病院の小児科部門を統括しています。

• 保健省より優れた業績に対する賞を受賞
• フランスのレジオンドヌール勲章を受章
• 世界医師会より「世界で最も思いやりのある医師」の一人に選出
• 米国小児腫瘍学グループおよび欧州がん学会のメンバー

オンダー・オフログル教授はの医療経験を持ち、ペンシルベニア大学およびカリフォルニア大学で骨・軟部腫瘍に関する高度な専門フェローシップ研修を受けています。

• 整形外科腫瘍外科を専門とする
• ロシアのイリザロフ科学センターにてイリザロフ手術の研修を修了
• 50以上の科学論文の著者または共著者
• 結合組織腫瘍学会および欧州整形外科学会の会員

小児血液学および腫瘍学において_doctor_9338_年以上の経験を持つドグル教授は、ビルニ大学病院にて小児の複雑な癌治療を専門としています。

• イスタンブール大学での小児腫瘍学の専門トレーニング
• 骨髄移植における専門知識
• 欧州骨髄移植学会のメンバー
• 複数の名門大学での助教授職を歴任

アパク医師は小児血液学および腫瘍学を専門とし、ビルニ大学病院にて骨髄移植およびCAR-T細胞療法の豊富な経験を有しています。

• イスタンブール大学ジェラパシャ校の小児血液腫瘍科部門を_doctor_6792_年以上主導
• 小児腫瘍治療に関する75本の国際論文を発表
• Turkish Pediatrics Archives誌の編集補佐
• トルコ小児科学会およびトルコ思春期医学協会の理事

整形外科医

Suna Emir教授は、1989年にハジェテペ大学医学部を卒業しました。1990年から1995年までハジェテペ大学で小児科の研修を修了しました。2001年には、ハジェテペ大学腫瘍学研究所で小児腫瘍学のサブスペシャリティを修了しました。2004年に准教授となりました。2004年から2009年まで、アンカラ・ディシュカプ小児保健・疾患教育研究病院で勤務し、そこで小児腫瘍科クリニックを設立しました。2009年には小児腫瘍科の副部長を務めました。2009年から2016年まで、アンカラ小児保健・疾患血液腫瘍学教育研究病院で小児血液腫瘍学の研修責任者を務めました。2019年からは、アティリム大学の小児保健・疾患学部の教授および創設メンバーを務めています。

小児科一般および小児血液腫瘍学の専門家です。研修医や専門医の教育に積極的に取り組んでいます。臨床的な関心分野は、出生から18歳までの小児疾患、リンパ腫、固形腫瘍、自家骨髄移植、貧血、出血性疾患、遺伝性血液疾患、血管腫およびその他の良性腫瘍、リンパ節腫大などです。

シャリテ腫瘍学センター長 – カイルホルツ博士は、複雑な癌の症例において最高レベルの専門知識を提供します。

• ユーイング肉腫に重点を置いた腫瘍学を専門とする
• ベルリン有数の腫瘍学センターを率いる

小児腫瘍学における_doctor_3339_年以上の専門経験を持つロペス・イボール医師は、HMモンテプリンシペ病院の小児血液・腫瘍科を率いています。

• ユーイング肉腫などの骨腫瘍治療の専門家
• 米国屈指の小児腫瘍学センターであるメリーランド大学で研修
• Hospital Universitario Clínica San Rafaelの元小児腫瘍科部長
• 国内外の学術誌に多数の論文を発表

アンゲリカ・エッガートは、ヨーロッパ最大級の大学病院であるシャリテ（Charité）の小児腫瘍科部長です。

• ヨーロッパのトップ病院で主要な部門を率いる
• 小児がん治療に特化
• 若い患者のための最新の臨床試験へのアクセス

小児血液腫瘍専門医であるKharya医師は、Artemis Hospitalsにて小児がんの骨髄移植を専門としています。

• 小児血液学および腫瘍学における専門知識
• 骨髄移植を専門とする
• 小児がんの治療に重点を置く

デミルカヤ教授は、メディカナ・ブルサ病院にて27 年にわたりユーイング肉腫に注力してきた小児腫瘍学の専門家です。

• ブルサ・ウルダグ大学小児腫瘍学レジデンシープログラムで研修
• 元ブルサ・ウルダグ大学医学部教員
• GATA小児血液・腫瘍・骨髄移植センターでの勤務経験
• 現メディカナ・ブルサ小児腫瘍学教授

シュルティ・ケイト医師はユーイング肉腫を専門とし、進行がんに対する免疫療法およびメトロノミック療法の専門知識を有しています。主要ながんセンターであるタタ記念病院で研修を受けました。

• タタ記念病院にて医療腫瘍学のDM（医学博士号）を取得
• ASCO、ESMOおよびその他の権威ある腫瘍学会の会員
• WCLC 2018にて肺がんに関する研究を発表
• 小児腫瘍および固形腫瘍の治療経験が豊富

ブランカ・ロペス・イボール医師は、HM Hospitalesの血液・小児腫瘍科を率いており、小児腫瘍学において31 年以上の経験を有しています。

• 小児および青少年の血液疾患およびがん疾患を専門とする
• WHOおよびユネスコの小児腫瘍学コンサルタント
• 深刻な健康問題を抱える子供たちを支援するFundación Jaime Alonso Abruñaの代表
• 国際小児腫瘍学会（SIOP）会員
• マドリード・コンプルテンセ大学およびCEUサン・パブロ大学の講師